NEXT Madrid

Dr. Josep Tabernero, who founded the IOB Institute of Oncology in Barcelona, coordinates both units. NEXT Oncology – Barcelona is in the Hospital Quirónsalud Barcelona and headed by site coordinator Dr. Elena Garralda. The opening of the two units boosts continued research activity and creates a great opportunity to promote clinical research in Spain.

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron Barcelona Hospital Campus, and Director of the Vall d’Hebron Institute of Oncology (VHIO).

He also co-directs the VHIO´s Gastrointestinal and Endocrine Tumours Group and the Research Unit for Molecular Therapy of Cancer (UITM) and is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with molecular targeted therapies, as well as phase II and III studies with novel chemotherapeutics.

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical Cancer Research. He has (co) authored approximately 450 peer-reviewed papers.

Dr. Tabernero was on the Executive Board of the European Society for Medical Oncology (ESMO) having served as ESMO President 2018 – 2019. He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and has been appointed as member of several Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and ESMO-GI/WCGIC meetings.

Dr Boni received her MD with honors cum laude in 2005 from the Catholic University of Rome, Italy. In 2009, she completed her medical training in oncology at the “Agostino Gemelli” University Hospital in Rome, Italy. Her interest in clinical research led her to join as Clinical Researcher, the Pharmacogenomic lab at the Center for Applied Medical Research (CIMA), in Pamplona, Spain, working on translational oncology, mainly focused on predictive biomarkers discovery and precision medicine. She subsequently earned her PhD in medicine from the University of Navarra in 2011 for her work entitled “Role of miRNAs as predictive biomarkers in metastatic colorectal cancer” with honors cum laude. In 2013, she joined the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (Flims), Switzerland.

From 2011, Dr Boni focused her work on the design and clinical early drug development leading several clinical trials. She has participated as Principal Investigator and co-investigator in more than 200 phase ½ studies, including First-in-Human, immunotherapy trials, combinations of targeted therapies and immunotherapies, biomarker-driven trials and trials in molecularly selected populations with special emphasis on breast cancer, gynecological tumors and melanoma. She has pioneered the development of new anticancer drugs now approved such as larotrectinib, selpercatinib, dostarlimab, lurbinectedin. Dr Boni’s research interests include the Phase I and early drug development of new anticancer agents as well as molecular genetic targets, immunotherapies, antibody drug conjugates, epigenetics and precision medicine for cancer therapy.

She authored and co-authored several papers in peer-reviewed journals including New England Journal of Medicine and Nature as well as of communications at different national and international congresses. She served as Faculty Member for the American Society of Clinical Oncology and as Clinical Associated Professor of Medicine at the European University, Madrid. She has participated in setting up the Spanish Molecular Tumor Board at GETTHI and in her institution where she is coordinating the precision medicine program centered on molecular analysis of patients’ tumors and molecular prescreening including circulating DNA and expression profiling to select the best anti-cancer therapy for any single patient and for better delivering precision medicine in clinical practice. Dr. Boni is member of the American Society of Clinical Oncology and of the European Society of Medical Oncology. She serves as an ad-hoc reviewer of various oncology journals.

Edwin Bellido, MD, MSc, is a Medical Oncologist and Clinical Investigator in the NEXT Oncology Early Drug Development Unit at Hospital Universitario Quirónsalud Madrid. Edwin Bellido, received his medical degree from the Public University of Cusco in Peru, in the upper third, and immediately after completed a master's degree in research methodology in the area of health at the University of Salamanca, Spain. Edwin Bellido completed his medical oncology training at the Valencian Institute of Oncology in Valencia, Spain, with stays at the Gustave Roussy Hospital in France in the breast cancer unit and in the drug development and innovation unit, phase 1 trials. Edwin Bellido also developed programs related to finance in the health sector at the University of Piura in Peru and a program called "Mindset Digital" at the IESE business school.  He also participated as a collaborator and professor at the Human Business School founded in Barcelona, in the field of telemedicine. Currently in the academic field Edwin won a scholarship of excellence to study the Master in Molecular Oncology at the Universidad Rey Juan Carlos.  And is also leading a project of artificial intelligence in the early detection of cancer on digital biopsies. In the last years, Edwin Bellido have been focused on phase 1 trials, especially in gynecological tumors. His topics of interest include the application of new technologies in the early detection of cancer and the discovery of new biomarkers to help patients which is my underlying motivation that drives me every day.

Jesús Fuentes Antrás, MD, MSc, is a Medical Oncologist and Clinical Investigator in the NEXT Oncology Early Drug Development Unit at Hospital Universitario Quirónsalud Madrid. Dr. Fuentes Antrás received his MD with honors in 2015 from the Universidad Autónoma de Madrid. He completed his Medical Oncology training at Hospital Clínico San Carlos in Madrid, and subsequently joined the Drug Development and Breast Cancer Units at Princess Margaret Cancer Centre – University Health Network in Toronto, Canada, as a clinical research fellow. Dr. Fuentes Antrás holds a Master’s degree in Molecular Oncology and is a PhD candidate in Translational Research in breast cancer from the Universidad Complutense de Madrid.   Dr. Fuentes Antrás has been recipient of early-career clinician and investigator merit awards from the Spanish Agency Against Cancer (AECC), the Spanish Society of Medical Oncology (SEOM), and the American Society of Clinical Oncology (ASCO), including a SEOM “Somos Futuro” for best medical oncology resident in the country, an ASCO Conquer Cancer Foundation Young Investigator Award, or a Novartis Young Canadian Investigator Award.  His clinical practice is focused on the care of patients participating in phase I trials testing novel anti-cancer molecules and including first-in-human studies. Dr Fuentes Antrás’ research interests include early drug development, multi-omic profiling, circulating biomarkers, and preclinical research models with the goal of advancing precision medicine for cancer patients.